Clinical Trial Detail

NCT ID NCT04231851
Title CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of California, Irvine
Indications

acute myeloid leukemia

Therapies

CPX-351 + Glasdegib

Age Groups: adult senior

Additional content available in CKB BOOST